{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023202","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.274920+00:00","generated_at":"2026-06-22T03:36:26.232696+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xenon Q3 net loss $37.2M; launches XEN1101 Phase 3 epilepsy program","bullets":["Revenue $0.1M vs $8.1M YoY; no Neurocrine milestone in Q3 2022.","Cash $752.2M as of Sep 30, 2022; expected runway into 2026.","XEN1101 Phase 3 trials X-TOLE2, X-TOLE3 (FOS) and X-ACKT (PGTCS) initiated.","X-NOVA MDD Phase 2 topline data expected Q3 2023.","R&D expenses $29.4M, up 56% YoY, driven by XEN1101 program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023202","json":"https://secwatch.observer/filing/0000950170-22-023202.json","markdown":"https://secwatch.observer/filing/0000950170-22-023202.md","text":"https://secwatch.observer/filing/0000950170-22-023202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/0000950170-22-023202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/xene-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:36:26.232696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a3524c78027d22e665159b753b2465553f741af","claim":"Xenon Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the six and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/0000950170-22-023202-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}